Thomas McHugh
CFO at Avadel Pharmaceuticals
from $240,000,000 to $260,000,000 We also are raising our guidance for patients on therapy to 3,400 to 3,600 patients by year end from 3,300 to 3,500 patients in prior guidance. While we are increasing revenue guidance, we are maintaining our previous full year cash operating expense guidance of 180,000,000 to $200,000,000 At this time, given the long term and unknown implications of industry wide changes around potential tariffs and policies impacting biotech, we want to also provide visibility into our near term expectations for Q2 performance. In that regard, we expect to generate 60,000,000 to $63,000,000 in net revenue during the second quarter of twenty twenty five, with cash operating expenses in the range of 45,000,000 to $50,000,000 And by providing this additional guidance during today's call, we hope to impart more certainty and confidence in our full year guidance as we close out the first half of the year. Overall, our increased guidance underscores our conviction in the commercial investments we made at the beginning of this year, what they were designed to achieve, while further confirming that Loomrise is on its way to achieving a billion in revenue. And turning to financial updates, in the quarter ended 03/31/2025, we reported net revenue of 52,500,000.0 and gross profit of $46,900,000 compared to net revenue and gross profit in the prior year quarter of $27,200,000 and $25,700,000 respectively.